Aug 9 (Reuters) - Medicenna Therapeutics Corp
* Medicenna reports first quarter fiscal 2018 financial results
* Qtrly loss per share $0.09
* Medicenna Therapeutics - will focus on completing patient enrollment for phase 2b clinical trial for mdna55, and expects interim top-line results in early 2018
* Medicenna Therapeutics - plans to begin enrolling patients for phase 2 clinical trial of mdna55 for treatment of other types of brain cancer in second half of 2017 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.